Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$5.15
EPS est.
$4.73
EPS surprise
+8.88%
1-day move
+2.43%
Amgen's earnings report showed a strong performance on EPS, exceeding expectations by nearly 9%. This positive surprise contributed to a 2.43% increase in the stock price. However, the lack of revenue data and management commentary leaves some uncertainty about the overall business outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.15 | $4.76 | +8.88% |
| Revenue | N/A | $8.6B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses. Operating in the Health Care sector, Amgen is known for its advancements in biologic medicines, which are crucial for treating conditions like cancer and autoimmune diseases.
Last quarter
In Q4-2025, Amgen reported an EPS of $5.29, exceeding expectations by 11.18%. Despite the positive earnings surprise, the stock experienced a slight decline the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+11.68%
Avg 1-day reaction
+0.07%
Analysts are generally optimistic about Amgen's upcoming earnings, expecting solid EPS and revenue figures. The company has consistently beaten EPS estimates in recent quarters, which adds to the positive sentiment.
Bull case
If Amgen continues its trend of beating EPS estimates, it could signal strong operational efficiency and product demand, potentially leading to a stock price increase.
Bear case
Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about future growth, leading to a negative reaction in the stock price.
Key metrics to watch
Earnings Per Share (EPS)
$4.76EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.
Revenue
$8.6BRevenue figures provide insight into the overall sales performance and market demand for Amgen's products.
The print will turn on these.
Q1
Will Amgen's EPS exceed the consensus estimate of $4.76?
A strong EPS performance could reinforce investor confidence and support a positive stock reaction.
Q2
What guidance will Amgen provide for future revenue growth?
Insights into future revenue expectations will be critical for assessing the company's growth trajectory and market positioning.
—
Est. EPS
$2.40
Est. Rev
$3.3B
Impl. Move
±19.0%
Why consensus could be wrong
The Street may be underestimating Amgen's ability to sustain its earnings momentum, given the recent strong performance and potential for new product launches.
Supporting evidence
Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
Insider trading patterns show mixed signals, which could indicate uncertainty about future performance.
Key risk
If EPS comes in below $4.50, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations.
Pre-commit to what would confirm each case.
The market is debating whether Amgen can maintain its strong earnings performance amid competitive pressures and market conditions.
Bull confirmed if
An EPS of $5.00 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $4.50 would confirm the bear case, raising concerns about profitability.
What the market is pricing for the move.
Implied Move
±4.3%
Historical Avg
±0.8%
The options market is pricing in a significant move around the earnings announcement, indicating that traders expect volatility.
Options are pricing a 4.3% move, while the stock has averaged only 0.8% over the last 8 quarters — setup is rich.
ATM IV
0.7%
30d HV
16.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
85.02%
of float
Insider
0.23%
of float
Holders
3,987
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
49,362,016 sh · $20.4B
9.13%
4.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Amgen beats expectations, history suggests a potential stock increase of around 0.6%, confirming strong operational performance.
In line / cautious
If results are in line with expectations but management is cautious, the stock may react neutrally as investors reassess future growth.
Miss
If Amgen misses expectations, history suggests a potential decline of around 0.4%, raising concerns about future profitability.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
5
2 buys·3 sells
Members
3
House + Senate
Est. Notional
$19,005.00–$110,000.00
disclosed dollar ranges
Most Active Members
3 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
35,250,101 sh · $14.6B
6.52%
0.7%
State Street Corporation
30,560,537 sh · $12.6B
5.65%
0.0%
Capital World Investors
29,075,329 sh · $12.0B
5.38%
-0.7%
Invesco Ltd.
16,320,446 sh · $6.7B
3.02%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Mixed
1 trade
Net selling
1 trade
Net selling
Recent Transactions
Traded Sep 22, 2026 · disclosed Oct 1, 2026
$1,001.00–$15,000.00
Traded Aug 26, 2026 · disclosed Sep 5, 2026
$1,001.00–$15,000.00
Traded Aug 12, 2026 · disclosed Sep 2, 2026
$1,001.00–$15,000.00
Traded Jun 5, 2026 · disclosed Jun 12, 2026
$1,001.00–$15,000.00
Traded Apr 17, 2026 · disclosed May 8, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.